
Alixia
Targeting the Tumor Ecosystem to address cancer drug resistance.
Monthly revenue–Not shared yet
Rank–Unranked
Last 30 days–Growth in MRR
Revenue per founder–– founders
About Alixia
Our compounds disrupt the metabolic and inflammatory triggers in both cancer and quasi-cancerous cells in the tumor microenvironment. By impacting multiple cell types, we are enabling effective, lasting cancer treatments.
Discover more startups
Browse the board →MRR
$251K
Last 30 days
-2%
Founder
Jacob Jacquet
MRR
$250K
Last 30 days
0%
Founder
Eugene Zolotarenko
MRR
$250K
Last 30 days
0%
Founder
Valon Asani